Tim Watts CEO of Shield Therapeutics talks about their recent £25m fundraise and what the funds will be used for
Episode 144, Mar 01, 2021, 01:12 PM
Tim Watts Chief Executive Officer of Shield Therapeutics #STX talks about their recent £25m fundraise and what the funds will be used for.
Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol) ®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield is quoted on AIM (STX).
Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol) ®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield is quoted on AIM (STX).